You are here: Industry Insights > Vyndaqel

News List

NICE rejects Pfizer’s rare heart disease treatment Vyndaqel pharmatimes
May 13, 2021
Pfizer’s Vyndaqel has been rejected by the UK National Institute for Health and Care Excellence (NICE) as a treatment for the rare heart condition transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
Pfizer's 4Q Revenues up 12% contractpharma
February 10, 2021
COVID-19 vaccine BNT162b2, which was granted an EUA in the U.S. in December 2020, contributed $154 million in sales in the quarter.
Financial Report; Pfizer contractpharma
November 06, 2020
Revenues down 4% in the quarter to $12.1 billion.
Pfizer receives CHMP recommendation for rare cardiomyopathy drug pharmaceutical-technology
December 17, 2019
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the authorisation of Pfizer’s Vyndaqel (tafamidis) ...
FDA OKs Vyndaqel and Vyndamax as First Treatments for Rare Heart Disease drugs
June 03, 2019
FDA OKs Vyndaqel and Vyndamax as First Treatments for Rare Heart Disease.
Pfizer's Vyndaqel, Vyndamax win US nod for rare disease pharmatimes
May 09, 2019
Pfizer's Vyndaqel, Vyndamax win US nod for rare disease.
FDA Approves New Treatments Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for Heart Disease Caused by Transthyretin Mediated Amyloidosis drugs
May 08, 2019
On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults.
FDA Approves Treatments for Heart Failure Caused by Rare Disease drugs
May 07, 2019
FDA Approves Treatments for Heart Failure Caused by Rare Disease.
FDA Approves New Treatments Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for Heart Disease Caused by Transthyretin Mediated Amyloidosis drugs
May 07, 2019
FDA Approves New Treatments Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for Heart Disease Caused by Transthyretin Mediated Amyloidosis.